DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Immutep
Immutep
Of Eftilagimod Alpha
AIPAC Global Webcast Slides
Immutep Novartis Patent
IMM Granted European Patent for IMP761
Immutep Limited Buy IMMP - NASDAQ March 8, 2019 Checkpoints on the Flipside of Immune Oncology
Licensing and Development Agreement for IMP731 for Immune Diseases
Efti (IMP321) in Melanoma TACTI-Mel (IO Combination) – Trial Design
Eftilagimod Alpha (IMP321)
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” Or the “Company”) Announces the Grant of Patent No
For Personal Use Only Use Personal for Inflammatory and Autoimmune Diseases Are Characterised by Activated T Cells That React Against the Patients’ Own Tissues
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” Or “The Company”), Is Pleased to Announce the Grant of Patent No
Immutep Limited
Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—R
The Global Leader in Developing LAG-3 Therapeutics
Immutep Patent Grant
Immutep Operational Update
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 12 March 2018 IMMUTEP ENTERS INTO CLINICAL TRIAL COLLABORATION and SUPPLY AGRE
Immutep Ltd. New Age Immune Regulator; Initiate with a Buy Rating and $8.30 Price Target
Top View
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 27 February 2015
Immutep (IMM) 22 April 2020 Speculative Investment
Immutep Positive Melanoma Trial Data
Immutep 20-F
COMPANY NOTE Immutep Limited (IMM-AU) OUTPERFORM Unlocking the Value of LAG-3 in Autoimmunity Target Price AUD0.078 Current Price AUD0.030
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC and HNSCC
Immutep Ltd (IMMP) Initiation Report
Immutep Announces Data Presentations at Upcoming Industry Conferences
Immutep Limited
Immutep Immunotherapy
Immutep Limited
Immutep Immunotherapy
Immutep AGM Presentation
The Global Leader in Developing LAG-3 Therapeutics
The Global Leader in Developing LAG-3 Therapeutics
Immutep Limited
Poster Which Was Presented at the SITC 2020